AMRX
Price
$13.41
Change
+$0.22 (+1.67%)
Updated
Jan 16 closing price
Capitalization
4.22B
46 days until earnings call
Intraday BUY SELL Signals
ELAN
Price
$24.53
Change
+$0.35 (+1.45%)
Updated
Jan 16 closing price
Capitalization
12.19B
39 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMRX vs ELAN

Header iconAMRX vs ELAN Comparison
Open Charts AMRX vs ELANBanner chart's image
Amneal Pharmaceuticals
Price$13.41
Change+$0.22 (+1.67%)
Volume$2.25M
Capitalization4.22B
Elanco Animal Health
Price$24.53
Change+$0.35 (+1.45%)
Volume$6.59M
Capitalization12.19B
AMRX vs ELAN Comparison Chart in %
AMRX
Daily Signal:
Gain/Loss:
ELAN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AMRX vs. ELAN commentary
Jan 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Hold and ELAN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 17, 2026
Stock price -- (AMRX: $13.41 vs. ELAN: $24.53)
Brand notoriety: AMRX: Not notable vs. ELAN: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 130% vs. ELAN: 126%
Market capitalization -- AMRX: $4.22B vs. ELAN: $12.19B
AMRX [@Pharmaceuticals: Generic] is valued at $4.22B. ELAN’s [@Pharmaceuticals: Generic] market capitalization is $12.19B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.06B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.55B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileELAN’s FA Score has 1 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • ELAN’s FA Score: 1 green, 4 red.
According to our system of comparison, AMRX is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 4 TA indicator(s) are bullish while ELAN’s TA Score has 6 bullish TA indicator(s).

  • AMRX’s TA Score: 4 bullish, 4 bearish.
  • ELAN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ELAN is a better buy in the short-term than AMRX.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а +3.47% price change this week, while ELAN (@Pharmaceuticals: Generic) price change was +4.52% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.04%. For the same industry, the average monthly price growth was +6.33%, and the average quarterly price growth was +18.14%.

Reported Earning Dates

AMRX is expected to report earnings on Mar 04, 2026.

ELAN is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.04% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($12.2B) has a higher market cap than AMRX($4.22B). AMRX has higher P/E ratio than ELAN: AMRX (1341.00) vs ELAN (350.43). ELAN YTD gains are higher at: 8.396 vs. AMRX (6.429). ELAN has higher annual earnings (EBITDA): 840M vs. AMRX (556M). ELAN has more cash in the bank: 505M vs. AMRX (201M). AMRX has less debt than ELAN: AMRX (2.69B) vs ELAN (4.02B). ELAN has higher revenues than AMRX: ELAN (4.59B) vs AMRX (2.94B).
AMRXELANAMRX / ELAN
Capitalization4.22B12.2B35%
EBITDA556M840M66%
Gain YTD6.4298.39677%
P/E Ratio1341.00350.43383%
Revenue2.94B4.59B64%
Total Cash201M505M40%
Total Debt2.69B4.02B67%
FUNDAMENTALS RATINGS
AMRX vs ELAN: Fundamental Ratings
AMRX
ELAN
OUTLOOK RATING
1..100
8326
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
34100
SMR RATING
1..100
9990
PRICE GROWTH RATING
1..100
3939
P/E GROWTH RATING
1..100
132
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ELAN's Valuation (94) in the Agricultural Commodities Or Milling industry is in the same range as AMRX (100) in the Pharmaceuticals Major industry. This means that ELAN’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (34) in the Pharmaceuticals Major industry is significantly better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that AMRX’s stock grew significantly faster than ELAN’s over the last 12 months.

ELAN's SMR Rating (90) in the Agricultural Commodities Or Milling industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that ELAN’s stock grew similarly to AMRX’s over the last 12 months.

ELAN's Price Growth Rating (39) in the Agricultural Commodities Or Milling industry is in the same range as AMRX (39) in the Pharmaceuticals Major industry. This means that ELAN’s stock grew similarly to AMRX’s over the last 12 months.

ELAN's P/E Growth Rating (2) in the Agricultural Commodities Or Milling industry is in the same range as AMRX (13) in the Pharmaceuticals Major industry. This means that ELAN’s stock grew similarly to AMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXELAN
RSI
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 5 days ago
65%
Declines
ODDS (%)
Bearish Trend 9 days ago
72%
Bearish Trend 3 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
58%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signal:
Gain/Loss:
ELAN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TAAGX14.940.05
+0.34%
Timothy Plan Small/Mid Cap Growth Cl A
FECGX33.57N/A
N/A
Fidelity Small Cap Growth Index
MFEJX189.06-0.16
-0.08%
MFS Growth R4
BGEFX14.52-0.05
-0.37%
Baillie Gifford International Growth 4
LRSQX13.15-0.05
-0.38%
Lord Abbett Small Cap Value R2